146257-03-6

Basic information

• Product Name: 1-BOC-3-METHOXYPYRROLIDINE
• Synonyms: 1-BOC-3-METHOXYPYRROLIDINE
• CAS NO: 146257-03-6
• Molecular Formula: C10H19NO3
• Molecular Weight: 201.26276
• Product Categories: pharmacetical
• Mol File: 146257-03-6.mol

Chemical Properties

• Boiling Point: 253.9±33.0 °C(Predicted)
• Appearance: /
• Density: 1.04±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -2.57±0.40(Predicted)
• CAS DataBase Reference: 1-BOC-3-METHOXYPYRROLIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-3-METHOXYPYRROLIDINE(146257-03-6)
• EPA Substance Registry System: 1-BOC-3-METHOXYPYRROLIDINE(146257-03-6)

Safety Data

• Hazardous Substances Data: 146257-03-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
1-BOC-3-METHOXYPYRROLIDINE is used as a building block for the synthesis of various pharmaceuticals and biologically active molecules. Its versatility and reactivity make it a valuable intermediate in the production of diverse chemical compounds with potential therapeutic uses.
Used in Organic Synthesis:
In the field of organic synthesis, 1-BOC-3-METHOXYPYRROLIDINE serves as a key intermediate for the preparation of a wide range of chemical compounds. The BOC protecting group allows chemists to temporarily shield reactive functional groups from unwanted reactions, facilitating the synthesis of complex molecules with greater ease and precision.
Used in Drug Development:
1-BOC-3-METHOXYPYRROLIDINE is employed in drug development as a precursor for the creation of new pharmaceutical agents. Its unique structural features and functional groups enable the design and synthesis of innovative drugs with improved efficacy, selectivity, and safety profiles.

Upstream product

• 103057-44-9 N-(tert-butoxycarbonyl)-3-hydroxypyrrolidine 
• 74-88-4 methyl iodide 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 62848-20-8 3-methoxy-pyrrolidine 
• 136725-50-3 (+/-)-3-methoxypyrrolidine hydrochloride 
• 1201657-89-7 tert-butyl 3-(4-bromo-1H-pyrazol-1-yl) pyrrolidine-1-carboxylate 

Relevant articles and documents

From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors

A high-throughput screening (HTS) of the Genentech/Roche library identified a novel, uncharged scaffold as a KDM5A inhibitor. Lacking insight into the binding mode, initial attempts to improve inhibitor potency failed to improve potency, and synthesis of

FUSED HETEROCYCLIC COMPOUND

The present invention relates to a fused heterocyclic compound having the Formula 1, which is useful as a platelet aggregation inhibitor, a method for preparing the same, and a pharmaceutical composition for inhibiting platelet aggregation comprising the same.

NEW BRADYKININ B1 ANTAGONISTS

The invention relates to compounds of formula (I) where in R1, R1a, R1b, R2, R3 and X, X1, X2, X3 have the meaning as cited in the description and the claims. Said compounds are useful as Bradykinin B1 antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.

Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof

The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (e.g., indazoles and benzothiazoles), which act as ligands for the α7 nACh receptor subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

1 H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZOISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF

The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of -disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the α7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.